• Artesunate: Mechanisms and Cancer Research Use

  2026-09-02

  Artesunate is an artemisinin derivative with reported ferroptosis and caspase-11-related pyroptosis activity in cancer research models. Its value is strongest when concentration, solvent, exposure conditions, and separate growth-arrest and cell-death endpoints are documented.

• TH287: Mapping MTH1-Dependent Cancer Vulnerability

  2026-09-01

  TH287, a potent MTH1 inhibitor, exposes how oxidized nucleotide stress can become a selective cancer-cell liability. This article presents a cell-state and assay-interpretation framework that extends beyond simple radiosensitization endpoints.

• β-Elemene Inhibits Adipogenesis via AMPK in 3T3-L1

  2026-09-01

  The reference study identifies β-Elemene as an inhibitor of MDI-induced adipogenesis and insulin-resistance-associated changes in 3T3-L1 cells. Its main contribution is linking reduced lipid accumulation and restored glucose consumption with regulation of the AMPK pathway, while also defining a practical in vitro workflow for metabolic research.

• Pol II Degradation and Transcription-Independent Cell Death

  2026-08-31

  The bioRxiv preprint argues that degrading RNA polymerase II (Pol II) activates cell death through mechanisms that cannot be explained solely by loss of transcription. Its main contribution is a conceptual and experimental separation of Pol II’s transcriptional function from a distinct survival-associated role, with implications for interpreting targeted protein-degradation studies.

• JNJ-26854165: From p53 Mechanism to Translation

  2026-08-30

  A translational framework for using JNJ-26854165 (Serdemetan) to interrogate HDM2–p53 biology, distinguish growth arrest from cell killing, and design more informative radiosensitization studies.

• MRTFA-KCNMB1 Control of Cancer Cell Stiffness

  2026-08-29

  Gajda et al. identify potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. Their integrated genetic, biophysical, electrophysiological, immune-cell, transcriptomic, and mouse-model data connect cancer-cell softening with immune evasion and metastatic colonization, while supporting BK-channel activation as a mechanistically actionable strategy.

• Spatial Metabolomics of POCD Hippocampal Lipids

  2026-08-29

  The reference study combines spatial metabolomics, enzyme imaging, ultrastructural analysis, and pharmacological rescue to connect hippocampal lipid disruption with postoperative cognitive dysfunction after cardiopulmonary bypass in rats. Its findings implicate CA1 lipid accumulation and altered iPLA2–SPT regulation while showing that DHA and myriocin can partially normalize metabolic and behavioral outcomes in this model.

• RPS6 as a Translational Readout in PDAC

  2026-08-28

  A mechanistic and strategic guide to using total RPS6 detection to connect LRRC8A–Caveolin-1 signaling, ribosome biogenesis, and pancreatic cancer growth.

• Clozapine N-oxide (CNO): Chemogenetic Guide

  2026-08-28

  Clozapine N-oxide (CNO) is a research metabolite and chemogenetic actuator used with engineered muscarinic DREADDs. Its main value is reversible neuronal activity modulation, while receptor expression, clozapine conversion, solubility, and experimental controls determine how results should be interpreted.

• Rottlerin and Clathrin-Mediated GCRV Entry

  2026-08-27

  Wang et al. used pharmacological inhibition, transmission electron microscopy, and RT-qPCR to show that genotype III grass carp reovirus enters CIK cells through a dynamin-dependent, clathrin-mediated, pH-sensitive pathway. The study positions Rottlerin as a useful pathway probe because it inhibited GCRV104 entry and replication, while also emphasizing that inhibitor data should be interpreted with orthogonal assays.

• Toremifene Workflows for Prostate Cancer Research

  2026-08-27

  Toremifene provides a practical selective estrogen-receptor modulator framework for connecting hormone-responsive phenotypes with migration, invasion, and calcium-signaling assays. This workflow-oriented guide shows how to benchmark growth inhibition while testing whether estrogen receptor modulation intersects with the TSPAN18–STIM1 axis described in prostate cancer metastasis research.

• NVP-BGJ398 phosphate: FGFR Workflow Guide

  2026-08-26

  NVP-BGJ398 phosphate combines potent FGFR1–3 inhibition with a workflow that connects phospho-signaling, genotype, cell phenotype, and tissue-level outcomes. This guide shows how to use BGJ-398 phosphate in biomarker-led cancer studies and FGFR3-focused skeletal disease models while avoiding common assay and formulation errors.

• Anlotinib hydrochloride in Angiogenesis Workflows

  2026-08-26

  Build more informative angiogenesis experiments by pairing Anlotinib hydrochloride with migration, tube formation, receptor-phosphorylation, and pathway-readout assays. Its coordinated activity against VEGFR2, PDGFRβ, and FGFR1 helps distinguish broad angiogenic signaling suppression from single-pathway effects.

• DMXAA (Vadimezan) Workflows for Tumor Vascular Studies

  2026-08-25

  DMXAA (Vadimezan) enables mechanism-guided studies of tumor endothelial apoptosis, VEGFR2-linked angiogenesis, and vascular disruption. This practical workflow also shows how to compare direct vascular injury with the vessel-normalization and immune-infiltration model emerging from endothelial STING-JAK1 research.

• Fluoxetine HCl: From Assay Signal to Behavior

  2026-08-25

  Fluoxetine HCl is a selective serotonin reuptake inhibitor used to connect serotonin transporter pharmacology with 5HT2C physiology and behavioral neuroscience. This guide presents an endpoint-aware framework for interpreting neurogenesis, synaptic plasticity, motivation, and stress resilience experiments without conflating molecular activity with therapeutic outcome.

451 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page